Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Preparing for phase II/III HIV vaccine trials in Africa.

Vardas E, Buttò S, Glashoff R, Malnati MS, Poli G, Clerici M.

Microbes Infect. 2005 Nov;7(14):1436-44. Epub 2005 Sep 26.

PMID:
16257561
2.

Human trials of experimental HIV vaccines.

Burke DS.

AIDS. 1995;9 Suppl A:S171-80. Review. No abstract available.

PMID:
8819583
3.

Therapeutic vaccine trails in Thailand.

Churdboonchart V.

J HIV Ther. 2004 Sep;9(3):57-9. Review.

PMID:
15534562
4.

Building collaborative networks for HIV/AIDS vaccine development: the AVIP experience.

Ferrantelli F, Buttò S, Cafaro A, Wahren B, Ensoli B.

Springer Semin Immunopathol. 2006 Nov;28(3):289-301. Epub 2006 Sep 16. Review.

PMID:
16983452
5.

Development of an AIDS vaccine: a daunting epidemiological challenge.

Nathanson N, Mathieson BJ.

Eur J Epidemiol. 2005;20(2):123-6. No abstract available.

PMID:
15792276
6.

Thailand's Prime-Boost HIV Vaccine Phase III.

Trinvuthipong C.

Science. 2004 Feb 13;303(5660):954-5. No abstract available.

PMID:
14963308
7.

HIV vaccines. Viral envelope fails to deliver?

Bolognesi DP, Matthews TJ.

Nature. 1998 Feb 12;391(6668):638-9. No abstract available.

PMID:
9490406
8.

Challenges to conducting HIV preventative vaccine trials with adolescents.

McClure CA, Gray G, Rybczyk GK, Wright PF.

J Acquir Immune Defic Syndr. 2004 Jun 1;36(2):726-33. Review.

PMID:
15167292
9.

What constitutes efficacy for a human immunodeficiency virus vaccine that ameliorates viremia: issues involving surrogate end points in phase 3 trials.

Gilbert PB, DeGruttola VG, Hudgens MG, Self SG, Hammer SM, Corey L.

J Infect Dis. 2003 Jul 15;188(2):179-93. Epub 2003 Jul 1.

PMID:
12854072
10.

Public health. A sound rationale needed for phase III HIV-1 vaccine trials.

Burton DR, Desrosiers RC, Doms RW, Feinberg MB, Gallo RC, Hahn B, Hoxie JA, Hunter E, Korber B, Landay A, Lederman MM, Lieberman J, McCune JM, Moore JP, Nathanson N, Picker L, Richman D, Rinaldo C, Stevenson M, Watkins DI, Wolinsky SM, Zack JA.

Science. 2004 Jan 16;303(5656):316. No abstract available.

PMID:
14726576
11.

Pox-Protein Public Private Partnership program and upcoming HIV vaccine efficacy trials.

Russell ND, Marovich MA.

Curr Opin HIV AIDS. 2016 Nov;11(6):614-619. Review.

PMID:
27636503
12.

Support for the RV144 HIV vaccine trial.

Belshe R, Franchini G, Girard MP, Gotch F, Kaleebu P, Marthas ML, McChesney MB, McCullough R, Mhalu F, Salmon-Ceron D, Sekaly RP, van Rompay K, Verrier B, Wahren B, Weissenbacher M.

Science. 2004 Jul 9;305(5681):177-80; author reply 177-80. No abstract available.

PMID:
15247455
13.

South African village prepares for first HIV vaccine trial.

Connett H.

Nat Med. 2000 Nov;6(11):1199-200. No abstract available.

PMID:
11062516
14.

Policy rebuttal. HIV vaccine trial justified.

McNeil JG, Johnston MI, Birx DL, Tramont EC.

Science. 2004 Feb 13;303(5660):961. No abstract available.

PMID:
14963313
15.

Controversial HIV vaccine enters phase III trials amid skepticism.

[No authors listed]

AIDS Alert. 1998 Dec;13(12):133-4, 136.

PMID:
11366059
16.

HIV/AIDS. Hedged bet: an unusual AIDS vaccine trial.

Cohen J.

Science. 2005 Aug 12;309(5737):1003. No abstract available.

PMID:
16099960
17.

[HIV/AIDS vaccines: heading for new vaccine approaches?].

Girard MP.

Bull Soc Pathol Exot. 2008 Jun;101(3):220-6. French.

PMID:
18681215
18.

Past, present and future of HIV vaccine trials in developing countries.

Esparza J, Osmanov S, Pattou-Markovic C, Touré C, Chang ML, Nixon S.

Vaccine. 2002 May 6;20(15):1897-8. Review.

PMID:
11983240
19.

The HIV vaccine pipeline, from preclinical to phase III.

Schultz AM, Bradac JA.

AIDS. 2001;15 Suppl 5:S147-58. Review. No abstract available.

PMID:
11816163
20.

Army HIV vaccine to undergo clinical trial as rival is halted.

Check E.

Nature. 2002 Mar 7;416(6876):6. No abstract available.

PMID:
11882860

Supplemental Content

Support Center